

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
March 11, 2009**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Helix BioPharma Corp.**

**File No. 000-53508 - CF# 22923**

---

Helix BioPharma Corp. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on November 25, 2008.

Based on representations by Helix BioPharma Corp. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

|             |                        |
|-------------|------------------------|
| Exhibit 4.1 | through July 31, 2013  |
| Exhibit 4.2 | through July 31, 2013  |
| Exhibit 4.3 | through April 28, 2015 |
| Exhibit 4.4 | through July 31, 2013  |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jeffrey Riedler  
Assistant Director